First launch for GSK's combination BPH drug Combodart
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's combination benign prostatic hyperplasia (BPH) drug Combodart (dutasteride 0.5mg/tamsulosin hydrochloride 0.4mg) has been launched in the UK, its first market.